Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
baicalin + metformin
- Development stage
- Preclinical
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Baicalin + metformin is a combination therapy consisting of baicalin, a flavonoid compound derived from the traditional Chinese medicinal herb Scutellaria baicalensis (黄芩), and metformin, a first-line oral antihyperglycemic agent widely used for type 2 diabetes. Baicalin exhibits anti-inflammatory, antioxidant, and insulin-sensitizing effects. It has been shown to activate the IRS/PI3K/Akt signaling pathway in hepatocytes, enhance glucose uptake, promote glycogen synthesis, and modulate gut microbiota composition. Metformin primarily acts by reducing hepatic gluconeogenesis and increasing peripheral insulin sensitivity without stimulating insulin secretion. The combination has been studied in preclinical models for synergistic effects on improving metabolic parameters such as glycemic control and insulin resistance in conditions like type 2 diabetes mellitus (T2DM) and polycystic ovary syndrome (PCOS)[1][4][5]. Both agents have distinct but potentially complementary mechanisms targeting glucose metabolism.
- Other names
- 黄芩苷联合二甲双胍
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)ND1 (Mitochondrial electron transport chain complex I)SLC2A4 (Solute carrier family 2 facilitated glucose transporter member 4)
Beyond the preview
Go deeper on baicalin + metformin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on baicalin + metformin.